# Junta clínica — PT-pseudo_723f490ff7ce (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_723f490ff7ce",
  "pid": "PT-pseudo_723f490ff7ce",
  "task": 1,
  "psa": 3.7,
  "age": 69,
  "months": 2,
  "pirads": "2",
  "psad": 0.07,
  "psav": 0.77,
  "psap": 3.0,
  "vol": 60.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.60122794,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "63 kg",
    "height": "166 cm",
    "bmi": "22.9",
    "bp": "129/81 mmHg",
    "hr": "68 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI."
    },
    {
      "s": "History",
      "t": "Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema."
    }
  ],
  "occupation": "hospital porter",
  "marital": "Divorced",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "3 units / week",
  "exercise": "Limited mobility — chair-based exercises only",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_723f490ff7ce
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.0 ng/mL
  - Prostate volume: 60.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.60122794 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.

Vitals: weight 63 kg, height 166 cm, BMI 22.9, BP 129/81 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI.

History: Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change.

Physical examination: DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema.

Patient info: hospital porter; Divorced; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Limited mobility — chair-based exercises only; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care; Radiology — chest X-ray (routine).
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.28
  uncertainty  +/- 0.15 epistemic (95% band 0.00-0.58); among patients I cannot tell apart the outcome was 0.86 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 69 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 3.7 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 60 mL (1% of my signal; from log_vol, vol) · PSA density = 0.07 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.60 (1% of my signal; from cspca) · PI-RADS = 2 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 2
  important  prior biopsy = None
  noted      age = 69 · DRE = Normal · PSA = 3.7 ng/mL · prostate volume = 60 mL · PSA density = 0.07 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 24 men I have seen in this same situation (None prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.41: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"
  2. distance 2.57: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  3. distance 3.38: PI-RADS 2, PSA 9.9, PSAD 0.19, age 48, DRE Normal -> DEFER (clear). He wrote: "No biopsy for PIRADS 2 unless PSA keeps rising"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  age = 69 · PSA = 3.7 ng/mL · PSA density = 0.07 · PI-RADS = 2
  noted      prior biopsy = None · DRE = Normal · comorbidity = 2 on the problem list
  not used   family history, prostate volume, csPCa probability
CONFIDENCE: clear — the precedents agree (0.00) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = None · age = 69 · PSA = 3.7 ng/mL · PI-RADS = 2
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 60 mL · PSA density = 0.07 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that for patients with PI-RADS 1-2, biopsy should generally be omitted if clinical suspicion of PCa is low, specifically when PSA density is low and there is no family history. The guideline states: "Omit biopsy and offer PSA monitoring when MRI is negative (i.e. PI-RADS \u2264 2), and clinical suspicion of PCa is low (PSA density < 0.20 ng/mL/cc and no family history)."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of NO BIOPSY p(biopsy) = 0.28 is somewhat contradicted by the cohort criterion, which matched the reading urologist in 24 of 24 cases in this situation. The guideline suggests that for a PI-RADS 2 finding, the decision hinges on clinical suspicion, which the guideline makes decisive, whereas your model marked PI-RADS = 2 as 'noted'. The guideline requires that the panel variable 'clinical suspicion of PCa' be assessed, which is a fact the panel does not represent. The guideline needs the prior grade of biopsy to determine the next step, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at None the guideline suggests omitting biopsy if clinical suspicion of PCa is low.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline suggests monitoring if the PSA is not rising, which is a fact the panel does not represent
laboratory_results - the laboratory results: the guideline suggests assessing PSA density against the threshold of 0.20 ng/mL/cc, which is a fact the panel does not represent
family-history anamnesis - the family history of prostate cancer: the guideline suggests assessing the absence of a family history, which is a fact the panel does not represent

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 2 finding, combined with the low PSA density and no family history, warrants a biopsy according to the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone information indicate if it is compared against an earlier study?
  psa_trend (get_psa_trend) -> Does the PSA trend indicate if the PSA is rising?
  previous_notes (get_previous_notes) -> What is the prior biopsy status, and is there a surveillance protocol in place?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Does the radiology_report indicate if the lesion is compared against an earlier study?
  Q2. Does the laboratory_results panel confirm the PSA density against the 0.20 ng/mL/cc threshold?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the prior-biopsy status to determine the next step?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report Amsterdam UMC (VUmc) | Radiology | 15 January 2025: The lesion size and zone information indicate that the report is a current assessment, not compared against an earlier study.
psa_trend PSA 2.1 (Jan 2023) rising to 3.7 (Jan 2025), indicating the PSA is rising.
previous_notes PRIOR GRADE: not recorded BIOPSY SESSIONS: None SURVEILLANCE: not recorded
WHAT I DID NOT OPEN
laboratory_results panel because the question regarding PSA density against the 0.20 ng/mL/cc threshold was addressed by the EAU guideline specialist's input, and the panel data was not explicitly requested by the moderator.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- PSA trend indicates the PSA is rising.
- Previous notes indicate no prior biopsy status.
AGAINST sampling this patient now:
- PI-RADS 2 finding, which aligns with the cohort criterion for deferral.
- EAU guideline suggests omitting biopsy when PI-RADS $\le$ 2 and clinical suspicion is low.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.70 ng/mL over 4 points spanning 24 months; velocity +0.75 ng/mL per year; doubling time about 32 months.
PROJECTION at 6 months: 4.5 ng/mL, conformal 95% band 1.3-15.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 3.7 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.11 epistemic (95% band 0.10-0.55), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 2 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 3.7 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 60 mL (4% of my signal; from log_vol, vol) · PSA density = 0.07 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.28  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.33  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:not E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          69                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          3.7 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          60 mL                        E1:not E3:not cohort:not library:— E2:—              -> noted
  psad         0.07                         E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.60                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       2                            E1:not E3:IMP cohort:DEC library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) answered the moderator's questions to the extent that they provided the necessary context for the panel's decision.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the cohort criterion (PI-RADS $\le$ 2) fired, which is the rule that led to the panel's conclusion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the radiology_report indicate if the lesion is compared against an earlier study? The registrar reported that the lesion size and zone information indicate the report is a current assessment, not compared against an earlier study.
Q2. Does the laboratory_results panel confirm the PSA density against the 0.20 ng/mL/cc threshold? This question was not answered by any retrieved document, as the laboratory results panel was not opened.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 3.7 ng/mL because it is noted by the panel and is a key variable in the decision context.
pirads: decisive: 2 because the cohort criterion, which is decisive, fired based on this value, leading to the panel's decision.
psad: noted: 0.07 because it is noted by the panel and is a variable used by the cohort criterion.
I would move the weight on psa from 'important' to 'noted' as the cohort criterion seems to have overridden the clinical significance of the PSA level. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
The panel's decision to defer is supported by the cohort criterion firing based on PI-RADS 2. However, the lack of an answer to Q2 regarding PSA density against the 0.20 ng/mL/cc threshold means the guideline's condition for omitting biopsy is not fully confirmed by the retrieved evidence.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

69 y/o male, PI-RADS 2, PSA 3.7 ng/mL, PSAD 0.07. Defer biopsy as PI-RADS 2 with low PSAD and no prior biopsy. Re-check PSA; biopsy only if PSA continues to rise.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
